ArticleDiscover oncology2026
ATOH1 and NPAS1 are immune related prognostic biomarkers in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasic helix-loop-helix (bHLH) transcription factors are implicated in tumorigenesis, but their comprehensive role in colorectal cancer (CRC) remains unclear. This study aims to systematically characterize the bHLH family in CRC.
methodsTranscriptomic and clinical data from TCGA COAD/READ cohorts were analyzed as a discovery set and validated with GEO datasets (GSE39582, GSE17538). Differential expression, Kaplan-Meier survival, and Cox regression analyses identified prognostic bHLH genes. A prognostic risk model was constructed, and immune infiltration was assessed via TIMER2.0. Protein-protein interaction (PPI) networks and methylation associations were explored using STRING and MEXPRESS.
resultsWe identified 36 and 32 differentially expressed bHLH genes in colon and rectal adenocarcinoma, respectively. ATOH1 was an independent protective factor (HR = 0.467, P = 0.005), while NPAS1 was an independent risk factor (HR = 2.327, P = 0.001) for overall survival. ATOH1 expression positively correlated with CD8 + T-cell infiltration, whereas NPAS1 showed a negative correlation. A prognostic model constructed using ATOH1 and NPAS1, which remained significant in the multivariate regression analysis, together with T stage, N/M stage, and MSI status demonstrated moderate predictive efficacy (AUC = 0.796). PPI network analysis suggested ATOH1 involvement in WNT/β-catenin signaling and NPAS1 in hypoxia-response pathways.
conclusionsThe first systematic analysis of the expression, prognosis and immune correlation of bHLH family in CRC. bHLH family members, particularly ATOH1 and NPAS1, represent potential biomarkers for prognosis and immune microenvironment evaluation in CRC. This integrated analysis provides a foundation for developing bHLH-targeted therapies and informs future immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.